Chester County News and Community Website
MALVERN, PA — Galera Therapeutics, Inc. (Nasdaq: GRTX), a key player in the pharmaceutical industry, recently unveiled its financial results for the fourth quarter and full year of 2023, which …
Galera Therapeutics Seeks Strategic Alternatives Amid Financial Setbacks and Regulatory Challenges Read More
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has recently shared its financial results for the full year of 2023, accompanying these figures with a business update for …
Orchestra BioMed: Continuing the Momentum into a Promising Future Read More
HORSHAM, PA — STRATA Skin Sciences, Inc. (NASDAQ: SSKN) recently made public its financial results for 2023’s fourth quarter and the entire year.
STRATA Skin Sciences Unveils 2023 Financial Results: A Look into an Evolving Business Model Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) recently announced financial results for the fourth quarter and full year ended December 31, 2023. The company also provided an update on …
FDA Clearance Paves Way for Aprea Therapeutics’ Next-Gen Cancer Drug, APR-1051 to Enter Phase 1 Clinical Trial Read More
MALVERN, PA — TELA Bio, Inc. (NASDAQ: TELA) recently revealed its financial performance for both the fourth quarter and the full calendar year ending on December 31, 2023. A cumulative …
TELA Bio Stands Tall With Consistent Growth, Novel Products, and a Promising Revenue Projection for 2024 Read More
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX), a biopharmaceutical company specializing in the development of treatments for solid tumors and gynecological cancers, has unveiled its financial outcomes for the …
Context Therapeutics Adjusts Strategy and Reports Financial Update Amidst R&D Pivot Read More
PHILADELPHIA, PA — The biotech company Cabaletta Bio, Inc. (Nasdaq: CABA), known for its pioneering work in autoimmune disease therapeutics, recently announced its financial results and business updates for the …
Cabaletta Bio Forges Ahead: A Strong Year Lays Groundwork for Groundbreaking Autoimmune Disease Therapies Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has unfurled its financial banners for the fourth quarter and full year closing December 31, 2023. Alongside these fiscal results, the company …
Targeting the Heart of the Matter – Mineralys Therapeutics In Pursuit of Transformative Treatments for Hypertension and Adjacent Conditions Read More
PHILADELPHIA, PA — Five Below Inc., the Philadelphia-based retailer much-loved for its wide range of products retailing for $5 or less, recently closed its fiscal year 2023 on a high …
Five Below Inc. Announces Record Sales and Profitability: A Strategic Success Story Amid Global Market Fluctuations Read More
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR), a company dedicated to transforming the lives of patients through the development of innovative therapies, has made notable strides in the …
Larimar Triumphs: Significant Strides Made on the Road to Treating Friedreich’s Ataxia Read More